🎉 M&A multiples are live!
Check it out!

Sangui Biotech Intl Valuation Multiples

Discover revenue and EBITDA valuation multiples for Sangui Biotech Intl and similar public comparables like Vivoryon Therapeutics, Pharming, and Galapagos.

Sangui Biotech Intl Overview

About Sangui Biotech Intl

Sangui Biotech International Inc develops pharmaceutical, medical and cosmetic products, through its subsidiary. The company develops oxygen carriers for providing oxygen transport in humans due to acute or chronic lack of oxygen and in the case of chronic wounds. It has also developed external applications of oxygen transporters in the form of sprays for healing chronic wounds and gels and emulsions for the regeneration of the skin. The products offered are artificial oxygen carriers; Chitoskin wound pads; and haemoglobin-based wound spray technology sold under the brand name Granulox. It derives revenue from licensing fees on sales of its wound spray product.


Founded

1996

HQ

United States of America
Employees

1

Financials

LTM Revenue n/a

LTM EBITDA n/a

EV

$0.9M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Sangui Biotech Intl Financials

Sangui Biotech Intl has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.

In the most recent fiscal year, Sangui Biotech Intl achieved revenue of $0.1M and an EBITDA of -$22K.

Sangui Biotech Intl expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Sangui Biotech Intl valuation multiples based on analyst estimates

Sangui Biotech Intl P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $0.1M $0.1M XXX XXX XXX
Gross Profit n/a $0.1M XXX XXX XXX
Gross Margin NaN% 95% XXX XXX XXX
EBITDA -$0.2M -$22K XXX XXX XXX
EBITDA Margin -282% -32% XXX XXX XXX
Net Profit n/a -$0.2M XXX XXX XXX
Net Margin NaN% -287% XXX XXX XXX
Net Debt n/a $0.7M XXX XXX XXX

Financial data powered by Morningstar, Inc.

Sangui Biotech Intl Stock Performance

As of April 15, 2025, Sangui Biotech Intl's stock price is $0.

Sangui Biotech Intl has current market cap of $42K, and EV of $0.9M.

See Sangui Biotech Intl trading valuation data

Sangui Biotech Intl Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$0.9M $42K XXX XXX XXX XXX n/a

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Sangui Biotech Intl Valuation Multiples

As of April 15, 2025, Sangui Biotech Intl has market cap of $42K and EV of $0.9M.

Sangui Biotech Intl's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.

Analysts estimate Sangui Biotech Intl's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Sangui Biotech Intl and 10K+ public comps

Sangui Biotech Intl Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $0.9M XXX XXX XXX
EV/Revenue 12.6x XXX XXX XXX
EV/EBITDA -38.7x XXX XXX XXX
P/E -0.7x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF -6.2x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Sangui Biotech Intl Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Sangui Biotech Intl Valuation Multiples

Sangui Biotech Intl's NTM/LTM revenue growth is n/a

Sangui Biotech Intl's revenue per employee for the last fiscal year averaged $0.1M, while opex per employee averaged $0.2M for the same period.

Over next 12 months, Sangui Biotech Intl's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Sangui Biotech Intl's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Sangui Biotech Intl and other 10K+ public comps

Sangui Biotech Intl Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth 5% XXX XXX XXX XXX
EBITDA Margin -32% XXX XXX XXX XXX
EBITDA Growth -88% XXX XXX XXX XXX
Rule of 40 (SaaS-only) n/a XXX XXX XXX XXX
Revenue per Employee $0.1M XXX XXX XXX XXX
Opex per Employee $0.2M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue 288% XXX XXX XXX XXX
R&D Expenses to Revenue 12% XXX XXX XXX XXX
Opex to Revenue 302% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Sangui Biotech Intl Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Sangui Biotech Intl M&A and Investment Activity

Sangui Biotech Intl acquired  XXX companies to date.

Last acquisition by Sangui Biotech Intl was  XXXXXXXX, XXXXX XXXXX XXXXXX . Sangui Biotech Intl acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Sangui Biotech Intl

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Sangui Biotech Intl

When was Sangui Biotech Intl founded? Sangui Biotech Intl was founded in 1996.
Where is Sangui Biotech Intl headquartered? Sangui Biotech Intl is headquartered in United States of America.
How many employees does Sangui Biotech Intl have? As of today, Sangui Biotech Intl has 1 employees.
Is Sangui Biotech Intl publicy listed? Yes, Sangui Biotech Intl is a public company listed on PINX.
What is the stock symbol of Sangui Biotech Intl? Sangui Biotech Intl trades under SGBI ticker.
Who are competitors of Sangui Biotech Intl? Similar companies to Sangui Biotech Intl include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Sangui Biotech Intl? Sangui Biotech Intl's current market cap is $42K
What is the current revenue growth of Sangui Biotech Intl? Sangui Biotech Intl revenue growth between 2023 and 2024 was 5%.
Is Sangui Biotech Intl profitable? Yes, Sangui Biotech Intl is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.